List of Excipients in Branded Drug CAMPRAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Carilion Materials Management	CAMPRAL	acamprosate calcium	68151-4760	CELLULOSE, MICROCRYSTALLINE
Carilion Materials Management	CAMPRAL	acamprosate calcium	68151-4760	CROSPOVIDONE
Carilion Materials Management	CAMPRAL	acamprosate calcium	68151-4760	MAGNESIUM SILICATE
Carilion Materials Management	CAMPRAL	acamprosate calcium	68151-4760	MAGNESIUM STEARATE

CAMPRAL Excipient Strategy and Commercial Opportunities for Acamprosate Calcium

Last updated: August 9, 2026

Campral, the branded formulation of acamprosate calcium, is a delayed-release 333 mg tablet for maintaining abstinence in patients with alcohol dependence. The commercial opportunity is primarily generic supply, formulation improvement, and differentiated adherence products rather than new-molecule exclusivity. The strongest technical focus is enteric protection, tablet robustness, dose flexibility, and lower-cost manufacturing.

What is Campral and how does its formulation work?

Campral contains acamprosate calcium, a synthetic compound used alongside psychosocial support to maintain abstinence after alcohol cessation. The FDA-approved product is a 333 mg delayed-release tablet administered as two tablets three times daily for patients with normal renal function.[1]

Attribute	Campral profile
Active ingredient	Acamprosate calcium
Strength	333 mg per tablet
Dosage form	Delayed-release, enteric-coated tablet
Standard adult dose	666 mg three times daily
FDA approval	2004
Original NDA	NDA 021431
Therapeutic category	Alcohol dependence maintenance therapy
Primary formulation challenge	Reliable delayed release with high drug loading
Key renal limitation	Contraindicated in severe renal impairment
Food effect	Food reduces systemic exposure, although the product is generally administered three times daily

Acamprosate is highly water-soluble but has low and variable oral bioavailability. The product label reports an absolute bioavailability of approximately 11% and a food-related reduction in exposure.[1] The enteric coating is therefore commercially important. It protects the tablet from immediate release in the stomach and supports release in the intestine.

Campral is not an extended-release product in the conventional once-daily sense. Its delayed-release design is intended to control the site of release, not to provide prolonged plasma exposure over an entire day.

What excipients are used in Campral?

The Campral label identifies a conventional high-load tablet core with an enteric film-coating system. Public labeling identifies core excipients including microcrystalline cellulose, crospovidone, magnesium silicate, and sodium starch glycolate. The coating system includes methacrylic acid copolymer, talc, titanium dioxide, and triethyl citrate.[1]

Formulation function	Campral excipient or excipient class	Commercial purpose
Diluent and compression aid	Microcrystalline cellulose	Supports tablet hardness and manufacturability
Superdisintegrant	Crospovidone	Promotes tablet breakup after coating dissolution
Superdisintegrant	Sodium starch glycolate	Supports rapid post-enteric disintegration
Glidant or processing aid	Magnesium silicate	Improves powder flow and compression behavior
Enteric polymer	Methacrylic acid copolymer	Delays release until intestinal pH
Anti-tacking and coating aid	Talc	Reduces sticking during coating
Opacifier	Titanium dioxide	Supports appearance and light protection
Plasticizer	Triethyl citrate	Improves film flexibility and reduces cracking

The formulation has a logical sequence: a high-drug-load tablet core, rapid disintegration after intestinal release, and a pH-sensitive polymer barrier. Any generic or reformulated product must reproduce the relevant performance characteristics, not merely match the excipient names.

Which excipient attributes are critical for a generic Campral product?

Enteric polymer selection

Methacrylic acid copolymers are the primary commercial platform for acamprosate delayed release. The polymer grade determines the pH at which the coating begins to dissolve. A lower dissolution threshold can cause premature release in the upper gastrointestinal tract, while a higher threshold can delay release too far into the intestine.

The development target is a reproducible dissolution profile with:

• Minimal release under acidic conditions.
• Rapid release at the specified intestinal pH.
• Low variability between coating lots.
• Adequate resistance to storage humidity.
• No cracking, peeling, or bridging during packaging and transport.

Alternative polymers, including hypromellose phthalate and hypromellose acetate succinate, may be technically viable. They create regulatory and development risk because the polymer grade, coating weight, solvent system, and dissolution profile would differ from the reference product.

Core disintegration

Acamprosate calcium has a high active load relative to the total tablet mass. The formulation must balance mechanical strength against rapid disintegration after the enteric film dissolves.

Crospovidone and sodium starch glycolate provide two different disintegration mechanisms. Crospovidone supports capillary action and rapid swelling-free breakup. Sodium starch glycolate expands on hydration. Their ratio can influence dissolution, tablet friability, and sensitivity to compression force.

A generic manufacturer may pursue:

• Lower coating weight with a more efficient enteric polymer.
• Direct compression if powder flow and compactability are adequate.
• Dry granulation to improve content uniformity and reduce dust.
• Wet granulation if the powder blend has poor flow or segregation risk.
• A reduced excipient count to lower cost and simplify supply.

The commercial risk is that aggressive excipient reduction can produce capping, lamination, delayed disintegration, or unstable dissolution after accelerated storage.

Lubrication and magnesium silicate

Magnesium silicate can assist powder flow and processing, but inorganic glidants may influence blend uniformity and compaction. Lubrication strategy matters because over-lubrication can reduce tablet tensile strength and slow liquid penetration.

A manufacturer evaluating substitutes should measure:

• Ejection force.
• Tensile strength.
• Friability.
• Disintegration after enteric coating.
• Acid-stage resistance.
• Buffer-stage dissolution.
• Stability at high humidity.

The optimal excipient package is not necessarily the lowest-cost package. It is the package that reduces batch failure and coating variability at commercial scale.

What formulation opportunities exist beyond the branded Campral tablet?

Lower-cost generic delayed-release tablets

The most immediate opportunity is an ANDA-compatible delayed-release tablet using generally recognized pharmaceutical excipients and a comparable dissolution profile. The core commercial advantages are established clinical use, an existing prescribing base, and no need to prove a new therapeutic indication.

Cost reductions may come from:

• Local sourcing of microcrystalline cellulose and disintegrants.
• A solvent-minimized aqueous coating process.
• Higher coating-pan utilization.
• Reduced tablet weight.
• Improved yield through automated coating inspection.
• Packaging optimization for moisture protection.

The principal barrier is not active-ingredient discovery. It is process control for a high-dose enteric tablet.

Smaller tablets and dose-flexible presentations

The standard regimen requires two 333 mg tablets three times daily. A smaller tablet could improve swallowing for patients with dysphagia or poor adherence. A 166.5 mg or 200 mg presentation could support titration or renal-adjusted clinical protocols, although the approved dosing and renal restrictions would not automatically transfer to a new strength.

A new strength would require regulatory justification and additional stability and dissolution work. It could also create commercial differentiation in a market where generic products are otherwise difficult to distinguish.

Once-daily or twice-daily formulations

A sustained-release or gastroretentive acamprosate formulation could target adherence, since the standard regimen is six tablets per day. The opportunity is commercially attractive but technically and regulatorily more demanding.

Acamprosate has low bioavailability and a complex relationship between release location, food intake, and absorption. A once-daily product would require evidence that the new release profile maintains adequate exposure and clinical performance. Depending on the design, the product could require a 505(b)(2) application rather than a conventional ANDA.[2]

Potential technologies include:

• Multiparticulate enteric pellets.
• Controlled-release matrix tablets.
• Osmotic delivery systems.
• Bilayer tablets combining immediate and delayed release.
• Enteric-coated mini-tablets contained in capsules.
• Polymer-coated granules with staged intestinal release.

The strongest commercial proposition is likely a twice-daily adherence product rather than a highly complex once-daily system. Twice-daily dosing could reduce development risk while addressing the burden of six daily tablets.

Sprinkle or multiparticulate products

Multiparticulates could support administration to patients who cannot swallow tablets. The product would need protection from premature release, acceptable taste, dosing accuracy, and compatibility with soft food or beverages.

Acamprosate’s high water solubility creates taste and local-exposure risks if the enteric barrier is damaged. A sprinkle formulation would therefore require robust individual-particle coating and packaging that prevents moisture uptake.

Orally disintegrating tablets

An orally disintegrating tablet could improve swallowing but would conflict with the need for delayed intestinal release unless the active ingredient is protected in enteric-coated particles. That design would increase manufacturing complexity and tablet-unit size.

An ODT is therefore a lower-priority opportunity than a coated multiparticulate or smaller conventional tablet. The main value would be administration convenience, not faster onset.

What FDA regulatory pathway applies to Campral formulation opportunities?

ANDA pathway for equivalent delayed-release tablets

A conventional generic Campral product would generally pursue an ANDA referencing the approved acamprosate calcium delayed-release tablet. The applicant would need to demonstrate pharmaceutical equivalence and bioequivalence, along with appropriate quality, stability, and dissolution data.[2]

Key development areas include:

• Same active ingredient and strength.
• Same dosage form and route.
• Comparable delayed-release performance.
• Bioequivalence under relevant study conditions.
• Manufacturing controls for enteric coating.
• Labeling consistent with the reference product, subject to FDA requirements.

Because acamprosate has low systemic bioavailability, conventional pharmacokinetic bioequivalence may require careful study design and validated analytical methods.

505(b)(2) pathway for differentiated delivery

A new release profile, new strength, new dosage form, or materially different administration method may require a 505(b)(2) application. This route can rely partly on existing FDA findings for acamprosate while requiring new clinical, pharmacokinetic, or safety data for the changed formulation.[2]

A 505(b)(2) product could support a stronger commercial position than an ANDA but would carry higher development costs and greater patent-certification exposure.

What is the patent and exclusivity position for Campral?

Campral’s original U.S. approval dates to 2004, and the brand-era regulatory exclusivity period has expired. Acamprosate calcium is an established active ingredient with generic competition. The principal opportunity is therefore post-exclusivity market participation rather than protection of a new chemical entity.[1][3]

Protection category	Commercial assessment
New chemical entity exclusivity	Expired
Original brand exclusivity	Expired
Generic delayed-release tablet	Primary market pathway
New formulation patent	Possible for novel release systems, particle engineering, or manufacturing processes
Method-of-use patent	Limited commercial value unless tied to a differentiated, enforceable indication
Orange Book risk	Must be assessed against current FDA listings before launch
Paragraph IV opportunity	Potentially relevant only if an unexpired listed patent covers the reference product or a listed formulation

A manufacturer developing a simple generic tablet should not assume that historical brand patents create a current launch barrier. A manufacturer developing a new controlled-release system should conduct a separate freedom-to-operate review covering enteric polymers, multiparticulate coatings, release-control technologies, and manufacturing processes.

Which companies are competing in the acamprosate market?

The competitive field includes the branded Campral product and multiple generic suppliers. Generic competition is generally based on:

• Unit price.
• National wholesaler access.
• Medicaid and managed-care contracts.
• Backorder performance.
• Manufacturing reliability.
• Packaging options.
• Ability to maintain supply during active-ingredient or coating-material shortages.

For a conventional generic, formulation differentiation is limited. The most defensible commercial positions are reliable supply, competitive cost of goods, and a product presentation that improves dispensing efficiency.

A differentiated product could compete through adherence rather than price. A twice-daily formulation, smaller tablet, or sprinkle product could support a premium reimbursement strategy if it demonstrates better persistence or reduced treatment discontinuation.

What manufacturing and supply-chain barriers affect acamprosate products?

Acamprosate calcium is not generally viewed as a biologic or highly complex active ingredient. The manufacturing barriers are formulation and process related.

Active-ingredient and excipient supply

The main supply risks involve:

• Qualified acamprosate calcium suppliers.
• Consistent particle-size distribution.
• Moisture control.
• Enteric-polymer availability.
• Coating-grade talc and titanium dioxide supply.
• Supplier changes affecting dissolution.
• Packaging materials with adequate moisture protection.

Excipient changes can alter coating adhesion, film permeability, tablet disintegration, and stability. Each change requires comparability assessment and, where appropriate, regulatory reporting.

Packaging requirements

Delayed-release tablets need packaging that limits moisture ingress. High-density polyethylene bottles with desiccant or high-barrier blister systems may be suitable, depending on stability data.

Packaging is a commercial variable. Bottles may reduce unit cost and simplify bulk dispensing. Blisters can improve dose organization but increase packaging cost. A calendar blister could support adherence for a six-tablet-per-day regimen, particularly in outpatient treatment programs.

How strong is the commercial opportunity for Campral excipient innovation?

The opportunity is moderate for generic supply and selective for differentiated delivery.

Opportunity	Development cost	Differentiation	Commercial outlook
Conventional generic delayed-release tablet	Low to moderate	Low	Stable, price-driven
Lower-cost coating process	Moderate	Moderate operational value	Attractive for high-volume suppliers
Smaller tablet	Moderate	Moderate	Useful for swallowing and dispensing
Twice-daily product	High	High	Potentially valuable if adherence benefit is demonstrated
Once-daily product	High to very high	High	Strong theoretical value, significant clinical risk
Sprinkle multiparticulate	High	High	Niche opportunity
ODT with enteric-coated particles	High	High	Technically complex and uncertain
New excipient platform	High	Moderate	Weak unless it materially improves release or stability

The best near-term strategy is a robust, low-cost delayed-release generic with manufacturing advantages. The best higher-value strategy is a reduced-frequency product supported by adherence and pharmacokinetic data.

Key Takeaways

• Campral is a 333 mg delayed-release acamprosate calcium tablet.
• The core formulation relies on microcrystalline cellulose, crospovidone, sodium starch glycolate, and magnesium silicate.
• The enteric coating uses a methacrylic acid copolymer system with talc, titanium dioxide, and triethyl citrate.
• Generic competition is the primary commercial route because original brand exclusivity has expired.
• The core technical challenge is balancing enteric resistance, intestinal release, tablet strength, and rapid post-coating disintegration.
• Smaller tablets, multiparticulates, and twice-daily products offer the clearest formulation differentiation.
• A conventional equivalent tablet generally fits the ANDA pathway; materially different delivery systems may require 505(b)(2) development.
• Commercial success depends more on manufacturing reliability, supply continuity, and adherence positioning than on novel excipient selection alone.

FAQs

Can acamprosate calcium be formulated without an enteric coating?

A non-enteric product would be materially different from Campral and would need to establish acceptable exposure, tolerability, and clinical performance. The enteric coating is central to the reference product’s delayed-release design.

Which excipient is most important in Campral tablets?

The methacrylic acid copolymer is the most important excipient class for release control. Its grade, coating weight, and process conditions determine acid resistance and intestinal dissolution.

Is a liquid acamprosate formulation commercially attractive?

A liquid formulation could address swallowing limitations but would face taste, chemical stability, dosing accuracy, and protection-from-acid challenges. It is less straightforward than a coated multiparticulate product.

Could a new acamprosate formulation receive orphan-drug protection?

Acamprosate treats alcohol dependence, a broad indication that generally does not support orphan designation. A narrowly defined rare-disease indication would require separate regulatory analysis.

Does a new excipient create patent protection for acamprosate?

The use of a known excipient alone is unlikely to create strong protection. Patent value would depend on a novel formulation architecture, measurable performance advantage, and claims that survive validity and obviousness scrutiny.

References

1. U.S. Food and Drug Administration. (2004). Campral (acamprosate calcium) delayed-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: Campral, NDA 021431.